Document Detail

Hydroxyurea in the management of thalassemia intermedia.
MedLine Citation:
PMID:  20001623     Owner:  NLM     Status:  MEDLINE    
Hydroxyurea (HU) is an antineoplastic agent that enhances fetal hemoglobin. The clinical significance induced by this compound is well known in sickle cell disease. This clinical significance could also be expected in beta-thalassemia patients. Although studies on beta-thalassemia major patients showed significant results, but these clinical responses are expected to be more in thalassemia intermedia (TI) patients because of lesser alpha/beta globin imbalance. Studies showed that HU therapy in TI patients has significant effects on increasing Hb levels that can cause reducing blood transfusion dependency and transfusion free in some patients, decreasing skeletal deformities and splenomegaly and increasing energy state. So HU therapy could be a useful alternative to blood transfusion in some TI patients.
Mehran Karimi
Related Documents :
15571023 - Experience with benign splenic disease.
9490563 - A patient with congenital dyserythropoietic anaemia type iii presenting with stillbirths.
25012873 - Very high residual volumes should not prevent transurethral resection of the prostate b...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Hemoglobin     Volume:  33 Suppl 1     ISSN:  1532-432X     ISO Abbreviation:  Hemoglobin     Publication Date:  2009  
Date Detail:
Created Date:  2009-12-16     Completed Date:  2010-05-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7705865     Medline TA:  Hemoglobin     Country:  England    
Other Details:
Languages:  eng     Pagination:  S177-82     Citation Subset:  IM    
Pediatric Department and Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents
Hemoglobins / analysis
Hydroxyurea / adverse effects,  therapeutic use*
Treatment Outcome
beta-Thalassemia / complications,  drug therapy*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Hemoglobins; 127-07-1/Hydroxyurea

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Heart disease in thalassemia intermedia.
Next Document:  Allogeneic stem cell transplantation in patients with ?-thalassemia: King Faisal Specialist Hospital...